Amgen Inc. and Sweden-based Biovitrum AB have expanded their alliance in a deal that gives Amgen worldwide rights to develop and commercialize potential diabetes treatments the companies have been developing. Amgen will pay Biovitrum upfront for expanded licensing rights, which it previously held only in North and South America, the European Union, Australia and New Zealand. Under the new agreement, Biovitrum will retain co-promotion rights in the Nordic region and Amgen will handle development and commercialization worldwide. Biovitrum will get royalties if a product is approved and sold and may receive other milestone payments.
